Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Celecoxib on Bone Ingrowth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male VA bilateral TKA patients 18 years or older with primary OA diagnosis~Exclusion Criteria:~* Patients with osteoporosis, hypersensitivity to Celebrex, allergy to tetracycline, Sulfonamides, patient with asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs.~* Patients who have had CABG.~* Patients with a history of peptic ulcer disease, duodenal ulcers.~* Female patients and patients diagnosed with unstable hypertension or hypotensive, with serum creative levels above 1.8-2.0 or diagnosed with severe renal disease.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Arm #1 (Type: EXPERIMENTAL): Celebrex treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).